Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Peregrine Pharmaceuticals has concluded patient recruitment in a Phase II trial to evaluate bavituximab in combination with carboplatin and paclitaxel in patients who were previously untreated non-small cell lung cancer (NSCLC).
Subscribe to our email newsletter
The aim of the trial is to compare the objective response rate (ORR) of carboplatin and paclitaxel with or without bavituximab in up to 86 patients with previously untreated locally advanced or metastatic NSCLC.
Earlier, bavituximab in combination with carboplatin and paclitaxel demonstrated encouraging survival and tumor response data.
Peregrine president and CEO Steven King said they are eager to analyze the early tumor response data from this trial as well as to follow the longer-term survival of these patients, as they continue to evaluate bavituximab’s broad therapeutic potential in additional ongoing clinical trials.